CLINICAL EFFICACY OF TACROLIMUS IN INFANTILE HAEMANGIOMA.

Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol 2005;22(5):383-406.

Hasan Q, Tan ST, Gush J, et al. Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Pediatrics 2000;105(1 Pt 1):117-20.

Leaute-Labreze C, Prey S, Ezzedine K. Infantile haemangioma. Part II. Risks, complications and treatment. J Eur Acad Dermatol Venereol 2011;25(11):1254-60.

Painter SL, Hildebrand GD. Review of topical beta blockers as treatment for infantile hemangiomas. Surv Ophthalmol 2016;61(1):51-8.

Sagi L, Zvulunov A, Lapidoth M, et al. Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases. Dermatology 2014;228(2):136-44.

Couto JA, Greene AK. Management of problematic infantile hemangioma using intralesional triamcinolone: efficacy and safety in 100 infants. J Plast Reconstr Aesthet Surg 2014;67(11):1469-74.

Garzon MC, Lucky AW, Hawrot A, et al. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am AcadDermatol 2005;52(2):281-6.

Qiu Y, Ma G, Yang J, et al. Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study. Clin Exp Dermatol 2013;38(8):845-50.

Kunzi-Rapp K. Topical propranolol therapy for infantile hemangiomas. Pediatr Dermatol 2012;29(2): 154-9.

McMahon P, Oza V, Frieden IJ. Topical timolol for infantile hemangiomas: putting a note of caution in ‘cautiously optimistic’. Pediatr Dermatol 2012;29(1): 127-30.

Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol 2012;29(1):28-31.

Khunger N, Pahwa M. Dramatic response to topical timolol lotion of a large hemifacial infantile haemangioma associated with PHACE syndrome. Br J Dermatol 2011;164(4):886-8.

Sun ZJ, Zhao YF, Zhang WF. Immune response: a possible role in the pathophysiology of hemangioma. Med Hypotheses 2007;68(2):353-5.

Hazen PG, Carney JF, Engstrom CW, et al. Proliferating hemangioma of infancy: successful treatment with topical 5% imiquimod cream. Pediatr Dermatol 2005;22(3):254-6.

Jia J, Zhao YF, Zhao JH. Potential roles of allograft inflammatory factor-1 in the pathogenesis of hemangiomas. Med Hypotheses 2007;68(2):288-90.

Lazaridou E, Giannopoulou C, Apalla Z, et al. Calcineurin inhibitors in the treatment of cutaneous infantile haemangiomas. J Eur Acad Dermatol Venereol 2010;24(5):611-24.